Lite Strategy, Inc. Impairment of Long-Lived Assets Held-for-use
Lite Strategy, Inc. (LITS) reported Impairment of Long-Lived Assets Held-for-use of $0 for the 12-month period ending 2025-06-30, per its 10-K filed 2025-09-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2025-11-14
- Lite Strategy, Inc. impairment of long-lived assets held-for-use for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Lite Strategy, Inc. impairment of long-lived assets held-for-use for fiscal 2024 was $10.90M.
- Lite Strategy, Inc. impairment of long-lived assets held-for-use for fiscal 2023 was $0.00.
| Period end | Impairment of Long-Lived Assets Held-for-use | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|
| 2025-06-30 | $0.00 10-K · filed 2025-09-26 | |
| 2024-06-30 | $10.90M 10-K · filed 2025-09-26 | |
| 2024-06-18 | $10.40M 10-Q · filed 2025-11-14 | |
| 2023-06-30 | $0.00 10-K · filed 2024-09-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |